2125472-55-9

Usage

Uses

Used in Pharmaceutical Industry:
(2-chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)phenyl) (4-(((S)-tetrahydrofuran-3-yl)oxy)phenyl)methanone is used as an impurity in Empagliflozin (E521510) for improving glycaemic control in diabetic rats. Its presence in the medication may have implications for the overall efficacy and safety profile of the drug, making it a significant compound to study and understand in the context of diabetes treatment.

Upstream product

• 90-80-2 D-Glucono-1,5-lactone 
• 403-43-0 4-fluorobenzoyl chloride 
• 456-22-4 4-Fluorobenzoic acid 
• 135700-53-7 4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-chlorobenzene 
• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 

Relevant academic research and scientific papers

Processes for the Preparation of SGLT-2 Inhibitors, Intermediates Thereof

The present invention relates to novel, improved processes for the preparation of sodium glucose co-transporter 2 (SGLT-2) inhibitors and novel intermediates thereof. More particularly, the present invention relates to a novel, improved process for the preparation of gliflozin compounds such as empagliflozin and dapagliflozin, intermediates thereof. The product obtained from the processes of present invention may be amorphous or crystalline, or in the form of amorphous/crystalline solid dispersions/solutions with pharmaceutically acceptable polymers and preparation process thereof. Also, the products obtained from the present invention may be used for the preparation of medicaments for the prevention and/or treatment of diseases and conditions associated with SGLT-2 inhibition.

PROCESS FOR PREPARING SGLT2 INHIBITORS AND INTERMEDIATES THEREOF

The present invention provides processes for preparing SGLT2 inhibitors, such as dapagliflozin and empagliflozin.